Duality plans Hong Kong IPO to fund trials of BioNTech-partnered ADCs and beyond

China’s Duality Biotherapeutics has filed paperwork for a Hong Kong IPO, seeking an undisclosed sum to power a broad pipeline of antibody-drug conjugates toward approval. The filing extends the recent flurry of IPO activity beyond the U.S. and into Asia.